Stay updated on Immunogenicity in Kids 6-35m: NBP607-QIV vs Agrippal Clinical Trial
Sign up to get notified when there's something new on the Immunogenicity in Kids 6-35m: NBP607-QIV vs Agrippal Clinical Trial page.

Latest updates to the Immunogenicity in Kids 6-35m: NBP607-QIV vs Agrippal Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has undergone significant revisions, including the removal of detailed descriptions of a clinical trial assessing the immunogenicity and safety of NBP607-QIV compared to Agrippal, while adding a new version revision and a mention of the study's location.SummaryDifference24%
- Check44 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.4, indicating a revision in the content.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check101 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check108 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Immunogenicity in Kids 6-35m: NBP607-QIV vs Agrippal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunogenicity in Kids 6-35m: NBP607-QIV vs Agrippal Clinical Trial page.